



BIOSENSORS
INTERNATIONAL
NEWS RELEASE

BIOSENSORS ANNOUNCES CLOSURE OF NETHERLANDS-BASED MANUFACTURING SUBSIDIARY

Singapore 2 October 2008 - Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP) announced that the Company is closing its Netherlands-based manufacturing subsidiary, Occam International, B.V. ("Occam"). On 26 May 2008, the Company publicly announced plans to either close or sell Occam and, prior to reaching its decision, explored several options, including the possible sale of the business.

Costs related to the closure of Occam are estimated to range from US\$3.0 to US\$ 4.0 million. The majority of these costs will relate to severance payments to be made to the Occam employees, most of whom are scheduled for dismissal on 1 November 2008. The remainder of the costs consists of rent due under the facility lease, write-offs of inventories related to Occam products and professional fees related to the closure. Anticipated annual cost savings to be realized in future years will range from US\$3.0 to US\$4.0 million.

"Our goal is to position Biosensors for future growth while enhancing profitability. As we evaluated the overall operation, it became apparent that continuing to manufacture similar lines of interventional cardiology products in both the Netherlands and Singapore is not cost effective," commented Mr. Michael Kleine, President and CEO. "We believe that products produced in our Singapore facility, including our flagship BioMatrix™ drug-eluting stent, will be sufficient to replace the loss of sales associated with Occam products. We will be considering various options with respect to the disposition of the remaining assets of Occam," concluded Kleine.

Media and Investor Relations Contact

Biosensors International Group

Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 6213 5708
Email: cm.loh@biosensors.com

Media Relations / Investor Relations Firm

United States

Allen & Caron Inc.

Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drug-eluting stent programs, *BioMatrix*™, *Axxion*™, and *BioFreedom*™, a completely polymer-free drug-eluting stent.

For more information, please visit www.biosensors.com

About BioMatrix®

BioMatrix™ offers the unique combination of an innovative anti-restenotic drug, Biolimus A9™, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability.

Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately leaving in place a biocompatible stent surface.

For more information, please visit www.biomatrix.com

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.